

"Express Mail" Label No. EL 769971313 US
Date of Deposit JANUARY 29, 2002

PATENT
Attorney Docket No.: 019957-013211US
Client Ref. No.: 100/162

BOX DIVISIONAL PATENT APPLICATION
U.S. Patent and Trademark Office
P. O. Box 2327
Arlington, VA 22202

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Michel Gilbert *et al.*

Application No.: Unknown

Filed: Herewith

For: LIPOPOLYSACCHARIDE α -2,3
SIALYLTRANSFERASE OF
CAMPYLOBACTER JEJUNI AND ITS
USES

Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

BOX DIVISIONAL PATENT APPLICATION
U. S. Patent and Trademark Office
P. O. Box 2327
Arlington, VA 22202

Sir:


The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. In accordance with 37 CFR §1.98(d), copies of the references can be found in Application No. 09/272,960, filed March 18, 1999 (Attorney Docket No. 019957-013210US). Also enclosed is a copy of the International Search Report for the corresponding PCT application. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant

information, and no inference should be made that the information and references are cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

Applicants believe that no fee is required for submission of this statement, since it is being submitted prior to the mailing of the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Kevin L. Bastian
Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
SF 1310387 v1

Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|--------------------------------|
| Substitute for form 1449A/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Application Number | Unknown |
| | | | | Filing Date | Herewith |
| | | | | First Named Inventor | Gilbert, Michel, <i>et al.</i> |
| | | | | Group Art Unit | Unassigned |
| | | | | Examiner Name | Unassigned |
| Sheet | 1 | of | 5 | Attorney Docket Number | 019957-013211US |

| U.S. PATENT DOCUMENTS | | | | | | |
|------------------------|--------------------------|----------------------|--------------------------------------|--|--|--|
| Examiner Initials * | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number | Kind Code ² (if known) | | | |
| | AA | US 5,352,670 | | Venot, <i>et al.</i> | 10-04-1994 | |
| | AB | US 5,374,541 | | Wong, <i>et al.</i> | 12-20-1994 | |
| | AC | US 5,545,553 | | Gotschlich | 08-13-1996 | |
| | AD | US 5,998,138 | | Stonnet, <i>et al.</i> | 12-1999 | |
| | AE | US 5,691,138 | | Guesdon, <i>et al.</i> | 11-1997 | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|--------------------------|--------------------------|-------------------------|---------------------|--------------------------------------|---|--|--|----------------|
| Examiner Initials * | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Office ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| | BA | EP | 173149A | | Hoechst AG | | | |
| | BB | PCT | WO 96/32491 | | | 10-17-1996 | | |
| | BC | PCT | WO 97/47749 | | | 12-18-1997 | | |
| | BD | PCT | WO 98/31826 | | | 07-1998 | | |
| | | | | | | | | |
| | | | | | | | | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1310387 v1

Please type a plus sign (+) inside this box → +

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | | | |
|--|---|----|---|--------------------------|--------------------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Complete if Known | |
| Sheet | 2 | of | 5 | Application Number | Unknown |
| | | | | Filing Date | Herewith |
| | | | | First Named Inventor | Gilbert, Michel, <i>et al.</i> |
| | | | | Group Art Unit | Unassigned |
| | | | | Examiner Name | Unassigned |
| | | | | Attorney Docket Number | 019957-013211US |

| OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS | | | | |
|---|-----------------------|--|----------------|--|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² | |
| | 1 | Aoki et al., "Analysis of the substrate binding sites of human galactosyltransferase by protein engineering," <i>EMBO J.</i> 9:3171-3178 (1990). | | |
| | 2 | Aspinall et al., "Lipopolysaccharides of <i>Campylobacter jejuni</i> Serotype O:19: Structures of Core Oligosaccharide Regions from the Serostrain and Two Bacterial Isolates from Patients with the Guillain-Barre Sundrome," <i>Biochemistry</i> 33: 241-249 (1994). | | |
| | 3 | Aspinall, et al. "Lipopolysaccharides of <i>Campylobacter jejuni</i> Serotype O:19: Structures of O Antigen Chains from the Serostrain and Two Bacterial Isolates from Patients with the Guillain-Barre Syndrome," <i>Biochemistry</i> 33: 250-255 (1994). | | |
| | 4 | Bradbury, <i>et al. J. of Clinical Microbiol.</i> , (September 1985) Vol. 22(3), pages 339-346, (abstract only) | | |
| | 5 | Chang, <i>et al. Glycobiology</i> , (May 1995) Vol. 5(3), pages 319-325. | | |
| | 6 | Frosch et al., "Evidence for a common molecular origin of the capsule gene loci in Gram-negative bacteria expressing group II capsular polysaccharides," <i>Mol. Microbiol.</i> 5: 1251-1263 (1991). | | |
| | 7 | Gilbert et al., "Cloning of the Lipooligosaccharide a-2-3-Sialyltransferase from the Bacterial Pathogens <i>Neisseria meningitidis</i> and <i>Neisseria gonorrhoeae</i> ," <i>J. Biol. Chem.</i> , 271:28271-28276 (1996). | | |
| | 8 | Gilbert et al., "Characterization of a recombinant <i>Neisseria meningitidis</i> a-2,3-sialyltransferase and its acceptor specificity," <i>Eur. J. Biochem.</i> 249: 187-194 (1997) | | |
| | 9 | Gibert, <i>et al.</i> "The Synthesis of Sialylated Oligosaccharides Using a CMP-Neu5Ac Synthetase/sialyltransferase Fusion" <i>Nature Biotechnology</i> (August 1998) Vol. 16, pages 769-772. | | |
| | 10 | Gillam and Smith, "Site-Specific Mutagenesis Using Synthetic Oligodeoxyribonucleotide Primers: I. Optimum Conditions and Minimum Oligodeoxyribo-Nucleotide Length," <i>Gene</i> 8:81-97 (1979). | | |
| | 11 | Guo, <i>et al. Applied Biochemistry and Biotechnology</i> , Oct-Nov 1997, Vol. 68 (1-2), pages 1-20. | | |
| | 12 | Imai, <i>et al. Cytobios</i> , (1994) Vol. 78(313), pages 115-122 (abstract only) | | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SF 1310387 v1

Please type a plus sign (+) inside this box →



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | | | |
|---|---|----|---|--------------------------|-------------------------|
| Substitute for form 1449B/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Application Number | Unknown |
| | | | | Filing Date | Herewith |
| | | | | First Named Inventor | Gilbert, Michel, et al. |
| | | | | Group Art Unit | Unassigned |
| | | | | Examiner Name | Unassigned |
| Sheet | 3 | of | 5 | Attorney Docket Number | 019957-013211US |

| OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS | | | |
|---|--------------------------|---|----------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | 13 | Ito et al., <i>Pure Appl. Chem.</i> , "Synthesis of Bioactive sialosides," 65:753 (1993). | |
| | 14 | Jamieson, et al. <i>Comparative Biochemistry and Physiology</i> , (1993) Vol. 105(1), pages 29-33. | |
| | 15 | Kajihara et al., "A Novel a-2,6-Sialyltransferase: Transfer of Sialic Acid to Fucosyl and Sialyl Trisaccharides," <i>J. Org. Chem.</i> 61: 8632-8635 | |
| | 16 | Kleene et al., "Expression of Soluble Active Human B1, 4 Galactosyltransferase in <i>Saccharomyces Cerevisiae</i> ," <i>Biochem. Biophys. Res. Commun.</i> 201:160-167 (1994). | |
| | 17 | Klohs, et al. <i>Cancer Res.</i> , (1979) Vol. 39(4), pages 1231-1238. | |
| | 18 | Korolik, et al. <i>Microbiology</i> , (November 1997) Vol. 143(pt11), pages 3481-3489. | |
| | 19 | Kuroki et al., " <i>Campylobacter jejuni</i> Strains from Patients with Guillain-Barre Syndrome Belong Mostly to Penner Serogroup 19 and Contain B-N-Acetylglucosamine Residues," <i>Ann Neurol</i> 33:243-247. (1993). | |
| | 20 | Mandrell, et al. <i>Immunobiology</i> , (1993) Vol. 187(3-5), pages 382-402. | |
| | 21 | Maskell, et al. <i>Mol. Microbiol.</i> , (1991) Vol. 5(5), pages 1013-1022, (abstract only) | |
| | 22 | Moran et al., "Molecular mimicry of host structures by bacterial lipopolysaccharides and its contribution to disease," <i>MS Immunol. Med. Microbiol.</i> 16:105-115 (1996). | |
| | 23 | Moran et al., "Molecular mimicry of host structures by lipopolysaccharides of <i>Campylobacter</i> and <i>Helicobacter</i> spp: implications in pathogenesis," <i>J. Endotoxin Res.</i> 3:521-531. | |
| | 24 | Nishiu et al., "Characterization of Rat N-Acetylglucosaminyltransferase I Expressed in <i>Escherichia coli</i> ," <i>Biosci. Biotech. Biochem.</i> 59 (9):1750-1752 (1995). | |
| | 25 | Parsons, et al. <i>Microbial Pathogenesis</i> , (1993) Vol. 14(4), pages 329-335. | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SF 1310387 v1

Please type a plus sign (+) inside this box → +

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | | | |
|--|---|----|---|--------------------------|--------------------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | Unknown |
| | | | | Filing Date | Herewith |
| | | | | First Named Inventor | Gilbert, Michel, <i>et al.</i> |
| | | | | Group Art Unit | Unassigned |
| | | | | Examiner Name | Unassigned |
| Sheet | 4 | of | 5 | Attorney Docket Number | 019957-013211US |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS | | | |
|--|-----------------------|---|----------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | 26 | Preston et al., "The Lipooligosaccharides of Pathogenic Gram-Negative Bacteria," <i>Crit. Rev. Microbiol.</i> 22:139-180. | |
| | 27 | Rest, et al. <i>Microbial Pathogenesis</i> , (1995) Vol. 19(6), pages 379-390. | |
| | 28 | Reuter et al., "Sialic Acids Structure - Analysis - Metabolism - Occurrence - Recognition," <i>Biol. Chem. Hoppe-Seyler</i> 377:325-342 | |
| | 29 | Roberts et al., "Generation of an antibody with enhanced <i>Nature</i> 328:731-734 (1987). | |
| | 30 | Ropper, "The Guillain-Barre Syndrome," <i>N. Engl. J. Med.</i> 326: 1130-1136. | |
| | 31 | Salloway, et al. <i>Infection Immunity</i> , (August 1996) Vol. 64(8), pages 2945-2949. | |
| | 32 | Smith, et al. <i>Microbial Pathogenesis</i> , (1995) Vol. 19(6), pages 365-377. | |
| | 33 | Steenbergen, et al. <i>Journal of Biochemistry</i> , (February 1998) Vol. 174(4), pages 1099-1108. | |
| | 34 | Skirrow, <i>Brit. Med. J.</i> "Campylobacter enteritis: a 'new' disease," 2:9-11 (1977). | |
| | 35 | Taylor, et al. <i>Antimicrobial Agents & Chemotherapy</i> (December 1983), Vol. 24(6), pp. 930-935, (abstract only). | |
| | 36 | Taylor, et al. <i>Antimicrobial Agents and Chemotherapy</i> , (May 1981) Vol. 19(5), pages 831-835 (abstract only) | |
| | 37 | Varki, "Biological Roles of Oligosaccharides: all of the theories are correct," <i>Glycobiology</i> 3:97-130. | |
| | 38 | Vogel, et al. <i>Medical Microbiology and Immunology</i> , (October 1997) Vol. 186(2-3), pages 159-166. | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SF 1310387 v1

Please type a plus sign (+) inside this box →



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **5** of **5**

Complete if Known

| | |
|------------------------|--------------------------------|
| Application Number | Unknown |
| Filing Date | Herewith |
| First Named Inventor | Gilbert, Michel, <i>et al.</i> |
| Group Art Unit | Unassigned |
| Examiner Name | Unassigned |
| Attorney Docket Number | 019957-013211US |

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---------------------|-----------------------|---|----------------|
| | 39 | Weiser, <i>et al. Critical Reviews in Clinical Laboratory Sciences</i> , (June 1981) Vol. 14(3), pages 189-239. | |
| | 40 | Weisgerber <i>et al.</i> , "Complete nucleotide and deduced protein sequence of CMP-neuAc: poly-a-2,8 sialosyl sialyltransferase of <i>Escherichia coli</i> K1," <i>Glycobiol.</i> 1:357-365 (1991). | |
| | 41 | Williams <i>et al.</i> , "Large-scale expression of recombinant sialyltransferases and comparison of their kinetic properties with native enzymes," <i>Glycoconjugate J.</i> 12: 755-761. | |
| | 42 | Wakarchuk <i>et al.</i> , "Mutational and crystallographic analyses of the active site residues of the <i>Bacillus circulans</i> xylanase," <i>Protein Sci.</i> 3:467-475 | |
| | 43 | Yamamoto <i>et al.</i> , "Purification and Characterization of a Marine Bacterial B-Galactoside a2,6-Sialyltransferase from <i>Photobacterium damsela</i> JT0160," <i>J. Biochem.</i> 120:104-110 (1996). | |
| | 44 | Yamamoto, <i>et al. J. of Biochemistry</i> , (January 1998) Vol. 123(1), pages 94-100. | |
| | 45 | Yamashiro, <i>et al. Glycoconjugate Journal</i> , (December 1995) Vol. 12(6), pages 894-900. | |

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SF 1310387 v1